Patient Centered Approaches to Preventing ASCVD Events

以患者为中心的预防 ASCVD 事件的方法

• 批准号: 10088461
• 负责人: SAMIA MORA
• 金额: $ 12.05万
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-01-01 至 2022-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10088461
• 关键词: Achievement; Address; Age; American Heart Association; Apolipoproteins B; Atherosclerosis; Automobile Driving; Award; Biological Markers; Blood Vessels; Cardiovascular Diseases; Cardiovascular system; Center for Translational Science Activities; Clinical; Collaborations; Coupling; Data; Diagnostic; Dimensions; Disease; Dyslipidemias; Education; Environment; Epidemiology; Event; Goals; Hospitals; IDL lipoproteins; Individual; Institution; Insulin Resistance; International; Investigation; LDL Cholesterol Lipoproteins; Lead; Lipids; Lipoproteins; Low-Density Lipoproteins; Measures; Mentors; Methods; Modernization; Molecular; Myocardial Infarction; Outcome; Participant; Pathway interactions; Patients; Pharmaceutical Preparations; Phenotype; Population; Postdoctoral Fellow; Prevention; Prevention Research; Preventive Medicine; Preventive therapy; Research; Research Activity; Research Personnel; Research Project Grants; Residual state; Resources; Risk; Risk Assessment; Risk Factors; Risk Management; Role; Science; Sum; Teaching Hospitals; Testing; Training; United Arab Emirates; Very low density lipoprotein; Woman; Women' s Health; Work; atherosclerosis risk; cardiovascular disorder prevention; cardiovascular disorder risk; cardiovascular health; cardiovascular risk factor; career; career development; case control; cost; cost effective; early onset; experience; high risk; high risk population; improved; inhibitor/antagonist; instrumentation; interest; lipoprotein triglyceride; medical schools; men; modifiable risk; mortality; multidisciplinary; novel; novel marker; novel therapeutic intervention; particle; patient oriented; patient oriented research; patient population; personalized medicine; pre-doctoral; premature; prevent; programs; prospective; recruit; research clinical testing; risk prediction; therapeutic target; training opportunity; young adult; young woman

7. Project Summary/Abstract As a cardiologist cross-trained in epidemiology, Dr. Mora has devoted her career to patient-oriented cardiovascular prevention research, focusing on modifiable risk factors, particularly lipids. Her independent contributions to the field of prevention resulted from a succession of in-depth studies examining the clinical utility of alternative lipid testing for cardiovascular risk prediction and management. She has served as a primary research mentor for more than twenty pre- and post-doctoral trainees in patient- oriented research projects. This has been highlighted in recent years by the achievements of her mentees in presenting their work nationally and internationally, with recognition by the American Heart Association Young Investigator Award and Best of Science abstract sessions. At the national level, Dr. Mora has also been active in promoting cardiovascular careers for women postdoctoral fellows. The candidate's experienced Mentoring Committee, ongoing patient-oriented research, exceptional institutional resources, and cost-effective collaborations provide a nurturing environment for the training and career development of junior investigators in patient-oriented cardiovascular disease research. The new research aims proposed in this award will evaluate lipid-related risk of atherosclerotic cardiovascular disease (ASCVD) among two populations of patients: those who are treated with statins and those who suffer from premature myocardial infarction. This has important clinical implications as new therapeutic strategies targeting lipids are rapidly emerging and already in clinical use. Currently, statin therapy is the cornerstone of dyslipidemia management and cardiovascular prevention and treatment. However, the majority of events (70%) among statin-treated individuals remain unprevented and common (1 in 7 statin-treated individuals). To this date, the mechanisms underlying this “residual risk” are unclear. While it is commonly believed that the risk factors responsible for ASCVD events among statin- treated individuals are the same as those among statin-naïve individuals, new data suggest there may be differences. Furthermore, while overall ASCVD mortality has declined in the US in the past decade, there has been no decrease or even an increase in mortality in younger adults recently, in particular for women. The impact of the study is to improve clinical outcomes by identifying lipid-related determinants of vascular risk and to grow and strengthen Dr. Mora's patient-oriented research program into a formal individualized program of mentoring with a focus on lipid risk factors. In sum, the proposed mentoring and research activities of this K24 project will provide numerous excellent training opportunities for junior investigators interested in patient- oriented cardiovascular research.

7.项目摘要/摘要作为心脏病专家，在流行病学领域进行了交叉训练，莫拉博士献身于她 面向以患者为导向的心血管预防研究的职业，重点是 脂质她对预防领域的独立贡献是由一系列深入研究产生的 检查替代替代性脂质测试的替代性心血管风险预测和管理的临床性。 曾担任MIS的主要研究导师 近年以来，她的受训者的成就已 在美国心脏协会年轻人的认可下在国内和国际上介绍这项工作 调查员奖和最佳科学摘要会议。 在促进妇女的心血管职业后，候选人的指导。 委员会，正在进行的面向患者的研究，卓越的机构资源和成本效益 合作为培训和职业发展提供了一个培养环境 以患者为导向的心血管疾病研究。 两种患者流行的动脉粥样硬化心血管疾病（ASCVD）的风险 他汀类药物和患有心肌梗死的人都很重要 临床意义作为针对脂质的新治疗策略正在迅速出现，并且已经处于临床状态 使用。 但是，在他汀类药物中的大多数事件（70％）仍未预防 和常见（七分之一的他汀类药物治疗的个体）。 不清楚。 新数据表明，接受治疗的个体是他汀类人中的惊奇。 差异。 最近，年轻人，尤其是女性的荒芜，甚至没有减少 该研究的影响是通过确定血管风险和脂质相关的决定因素来改善临床结果 将莫拉博士以患者为导向的研究计划成长和加强成正式的个性化计划 以脂质风险因素为重点。 项目将为对患者感兴趣的初级调查人员提供许多出色的培训机会 - 定向心血管研究。